Cell line · CVCL_1724
Papers93
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 93
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting O6-methylguanine-DNA Methyltransferase Deficiency in Preclinical Models of Extracranial Human Cancers with a Tumor-Selective DNA-Modifying Agent. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR Screening Identifies SMARCAL1 and MRN as Modulators of WRN Dependency in MSI-H Colorectal Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Soluble Uric Acid Drives CD8+ T-cell Exhaustion by Inducing KSR1-Mediated MAPK Hyperactivation. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AURKA-mediated destabilization of SAPS3 drives ferroptosis evasion via 7-dehydrocholesterol biosynthesis in colorectal cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Subcellular Redistribution of Endomembrane GPR15 Promotes NAD+-Mediated Metabolic Reprogramming and Boosts 5-FU Chemosensitivity in Colorectal Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The dysadherin/carbonic anhydrase 9 axis shapes an acidic tumor microenvironment to promote colorectal cancer progression. | Signal Transduct Target Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R-Loop Accumulation and DNA Repair Deficiencies. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| circ-EGFR is a predictor of response to Cetuximab and a potential target in colorectal cancer. | EMBO Mol Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Purinergic ecto-enzyme CD73 is a context-dependent tumor suppressor in colorectal cancer. | J Biol Chem | 2025 | Its Methods give the RRID and name the line | PubMed | |
| GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. | Mol Syst Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Clonal dispersal is associated with tumor heterogeneity and poor prognosis in colorectal cancer. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Asparagine synthetase and G-protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer. | Int J Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The dysadherin/MMP9 axis modifies the extracellular matrix to accelerate colorectal cancer progression. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1724/papers